scholarly journals Prognostic Role of MicroRNA-210 in Various Carcinomas: A Systematic Review and Meta-Analysis

2014 ◽  
Vol 2014 ◽  
pp. 1-10 ◽  
Author(s):  
Minmin Li ◽  
Xuelei Ma ◽  
Mei Li ◽  
Binglan Zhang ◽  
Juan Huang ◽  
...  
Keyword(s):  
Meta Analysis ◽  
Relevant Literature ◽  
Disease Free Survival ◽  
Hazard Ratio ◽  
Breast Cancers ◽  
Prognostic Role ◽  
Free Survival ◽  
Distant Relapse ◽  
Disease Free

Objective. Many studies have shown that microRNAs (miRNAs) could play a potential role as prognostic biomarkers of tumors. The aim of this study is to summarize the global predicting role of microRNA-210 (miR-210) for survival in patients with a variety of carcinomas.Methods. Relevant literature was identified using PubMed and the information in eligible studies has been extracted. Then meta-analysis of hazard ratio (HR) was performed to evaluate the prognostic role of the miR-210 in different tumors.Results. This meta-analysis included 9 published studies dealing with various carcinomas. For recurrence free survival or disease free survival (RFS/DFS), the combined hazard ratio (HR) and 95% confidence interval (95% CI) of higher miR-210 expression were 2.47 [1.36, 4.46], which could significantly predict poor survival in general carcinomas. MicroRNA-210 was also a significant predictor for overall survival (OS), metastasis free survival or distant relapse free survival (MFS/DRFS), and disease specific survival (DSS). Importantly, subgroup analysis suggested that higher expression of miR-210 correlated with worse RFS/DFS, OS, and MFS/DRFS, especially in breast cancer, which were 3.36 [2.30, 4.93], 3.29 [1.65, 6.58], and 2.85 [1.76, 4.62] separately.Conclusion. Our studies suggested that microRNA-210 could predict the outcome of patients with varieties of tumors, especially in breast cancers.

scholarly journals Prognostic Role of High Stathmin 1 Expression in Patients with Solid Tumors: Evidence from a Meta-Analysis

2018 ◽  
Vol 50 (1) ◽  
pp. 66-78 ◽  
Author(s):  
Qingyan Mao ◽  
Zhen Chen ◽  
Kun Wang ◽  
Renfang Xu ◽  
Hao Lu ◽  
...  
Keyword(s):  
English Literature ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
Progression Free Survival ◽  
Free Survival ◽  
Online Databases ◽  
Stathmin 1 ◽  
Tumor Types ◽  
Disease Free

Background/Aims: Several recent studies have demonstrated that Stathmin 1expression may be closely associated with prognosis in patients with various types of cancers. In the present study, we conducted a meta-analysis of all available studies in the English literature to assess the prognostic value of Stathmin 1expression in patients with solid cancers. Methods: The online databases PubMed, Embase, and Web of Science were searched for literature regarding Stathmin 1 and its association with patient outcomes associated with solid cancers. Results: A total of 23 articles including 26 studies that contained 5 335 patients were retrieved and analyzed. Our results indicated that high Stathmin 1 expression yielded a worse overall survival (OS) (hazard ratio [HR] = 2.17, 95% confidence interval [CI]: 1.81–2.60), disease-free survival (DFS) (HR = 2.46, 95% CI: 2.00–3.02), disease-specific survival (DSS) (HR = 1.98, 95% CI: 1.58– 2.47) and progression-free survival (PFS)/recurrence-free survival (RFS) (HR = 2.09, 95% CI: 1.51–2.89). Furthermore, the association of high Stathmin 1 expression with poor survival was significant even for sub-group analyses of different tumor types, ethnicities, methods used to calculate HRs, detected methods, and analysis types. Conclusion: In summary, this meta-analysis determined that high Stathmin 1 expression is associated with poor prognosis in patients with solid cancers and expression of this protein could be a clinically useful prognostic biomarker.

Prognostic Role of Estrogen Receptor Determination in Breast Cancer

1983 ◽  
Vol 69 (6) ◽  
pp. 527-530 ◽  
Author(s):  
Stefano Ciatto ◽  
Patrizia Bravetti ◽  
Gaetano Cardona ◽  
Luigi Cataliotti ◽  
Roberto Crescioli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Recent Literature ◽  
Disease Free Survival ◽  
Metastatic Breast ◽  
Prognostic Role ◽  
Free Survival ◽  
The Difference ◽  
Disease Free ◽  
Actuarial Method

The authors report on 283 primary, non-metastatic, breast cancer cases consecutively referred after surgery and followed-up from a minimum of 10 months to a maximum of 3.5 years. All cases were studied according to the presence of estrogen receptors (ER). ER presence was correlated with age and menstrual status, with ER+ cases more frequent in older patients. No correlation was found between ER and nodal status. Prognosis was evaluated in terms of disease-free survival at 2 years (actuarial method). No correlation between ER and survival was evident for N– cases, whereas a better prognosis was recorded for ER+N+ patients compared to ER-N+, although the difference was not statistically significant. The observed results are compared with recent literature data and agree with other recent reports, which did not confirm the previously undiscussed statement regarding the prognostic role of ER determination. According to these studies and to the present study, the prognostic role of ER determination seems at least questionable and particularly the postoperative adjuvant treatment of ER-N– cases should be reconsidered.

Prognostic Role of Hormone Receptors in Ovarian Cancer: A Systematic Review and Meta-Analysis

2013 ◽  
Vol 23 (1) ◽  
pp. 25-33 ◽  
Author(s):  
Dong Zhao ◽  
Fengmei Zhang ◽  
Wei Zhang ◽  
Jing He ◽  
Yulan Zhao ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Estrogen Receptor ◽  
Elevated Level ◽  
Hormone Receptors ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
Progression Free Survival ◽  
Free Survival ◽  
Disease Free

ObjectiveThe aim of this study was to summarize the global predicting role of hormone receptors for survival in ovarian cancer.MethodsEligible studies were identified and assessed for quality through multiple search strategies. Data were collected from studies comparing overall or progression-free/disease-free/relapse-free survival in patients with elevated levels of estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER2) with those in patients with lower levels. Studies were pooled, and combined hazards ratios (HRs) of ER, PR, and HER2 for survival were calculated, respectively.ResultsA total of 35 studies were included for meta-analysis (23 for ER, 19 for PR, and 8 for HER2). For overall survival, the pooled HR of PR reached 0.88 [95% confidence interval (CI), 0.82-0.95], which means that elevated PR level could significantly indicate better survival. In contrast, elevated levels of HER2 could predict worse outcome with an HR of 1.41 (95% CI, 1.05–1.89). Increased level of ER was not significantly prognostic (HR, 0.94; 95% CI, 0.87–1.01). For progression-free survival/disease-free survival/recurrence-free survival, elevated PR level also had predictive value for better outcome with a pooled HR of PR of 0.80 (95% CI, 0.67–0.95). Oppositely, elevated HER2 level could predict poorer outcome with an HR of 1.55 (95% CI, 1.11–2.16). Estrogen receptor failed to predict outcome with an HR of 0.90 (95% CI, 0.78–1.03).ConclusionsIn patients with ovarian cancer, elevated level of PR predicted favorable survival, and elevated level of HER2 was associated with worse survival.

scholarly journals Prognosis Value of Low microRNA-34a Expression in Human Gastrointestinal Cancer: A Meta-Analysis

2020 ◽  
Author(s):  
Yan-Ling Chen ◽  
Xiao-Lin Liu ◽  
Ling Li
Keyword(s):  
Meta Analysis ◽  
Disease Free Survival ◽  
Clinicopathological Characteristics ◽  
Cancer Prognosis ◽  
Expression Level ◽  
Significant Relation ◽  
Free Survival ◽  
Predictive Role ◽  
Disease Free

Abstract Background: Mounting evidence shows that microRNA-34a (miR-34a) is involved in cancer prognosis. Therefore, we summarize the predictive role of miR-34a for survival in patients with gastrointestinal cancers (GICs). Methods: All the eligible studies were searched by PubMed, Web of Science and EMBASE and survival results were extracted. Then, the hazard ratio (HR) with corresponding 95% confidence intervals (CIs) was calculated to evaluate the prognostic role of miR-34a in GICs. The association between miR-34a expression and clinicopathological characteristics was estimated by odds ratio (OR) and 95%CIs. Results: A total of 20 studies were included in this meta-analysis. For overall survival (OS), the lower miR-34a expression significantly predicted poorer outcome in GICs, with the pooled HR of 1.86 (95% CI: 1.52-2.28, P<0.01). For disease-free survival (DFS), progressive-free survival (PFS), and recurrence-free survival (RFS), the lower miR-34a expression revealed worse DFS/PFS/RFS with the pooled HR of 1.86 (95% CI: 1.31–2.63, P < 0.01). Significant relation of differentiation/TMN stage/lymphatic metastasis and the expression level of miR-34a was identified. Conclusion: This meta-analysis reveals that lower miR-34a expression is significantly connected with worse OS and DFS/PFS/RFS of GICs patients. In addition, miR-34a expression level is relatively lower in patients with lymph node metastasis than patients without, and decreased miR-34a expression level is linked to poor tumor differentiation and late TMN stage. MiR-34a may become a new factor for prognosis prediction and progression of GICs.

scholarly journals Prognostic significance of circRNAs expression in breast carcinoma patients: A meta-analysis

2021 ◽  
Author(s):  
Zizhen Zhou ◽  
Xiancai Li ◽  
Dewu Liu
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
Hazard Ratio ◽  
Breast Cancer Patients ◽  
Free Survival ◽  
Regulated Expression ◽  
Disease Free

AbstractObjectiveThe aim of our study was to systematically evaluate the prognostic effects of various circrnas and to explore the prognostic value of circRNAs in breast cancer patients.MethodsA systematical search was conducted on PubMed, Scopus, EMBASE, and the Cochrane Library databases. Eligible studies reporting on the association among circRNAs and prognostic values of breast cancer patients were included. Fixed-effects and random effects models were used to calculate the pooled hazard ratio values of overall survival and disease free survival. In addition, funnel plots were used to qualitatively analyze the publication bias.Results28 studies were included in our meta-analysis. The pooled hazard ratio values of overall survival and disease free survival related to different circRNAs expression in breast cancer patients were 1.68 (1.44-1.97), 2.63 (1.95-3.53).We have identified a total of 28 circRNAs including 19 significantly up-regulated expression circRNAs and 9 significantly down-regulated expression circRNAs in BC(breast cancer) patients. Moreover, all of them revealed mechanisms and have the function of promoting or inhibiting the proliferation, metastasis or invasion of breast cancer cells by acting on the corresponding target.ConclusionOverall, specific circRNAs are significantly associated with the prognosis of BC patients and potentially eligible for the prediction of patients survival. It also provides a potential value for clinical decision-making development and may serve as a promising circRNAs-based target therapy waiting for further elucidation.

scholarly journals Correlation of Computed Tomography Parameters with Histology, Stage and Prognosis in Surgically Treated Thymomas

Medicina ◽  
2020 ◽  
Vol 57 (1) ◽  
pp. 10
Author(s):  
Angelo Carretta ◽  
Stefano Viscardi ◽  
Piergiorgio Muriana ◽  
Paola Ciriaco ◽  
Alessandro Bandiera ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Ct Scan ◽  
Disease Free Survival ◽  
Tumor Stage ◽  
Tnm Staging ◽  
Prognostic Role ◽  
Free Survival ◽  
Staging Systems ◽  
Disease Free

Background and objectives: The histological classification and staging of thymic tumors remains a matter of debate. The correlation of computed tomography (CT) parameters with tumor histology and stage also still has to be completely assessed. The aim of this study was therefore to analyze the correlation of radiological parameters with histological and staging classifications of thymomas evaluating their prognostic role. Methods: Data of 50 patients with thymoma submitted to a complete surgical treatment between 2005 and 2015 were retrospectively analyzed. Tumors were classified according to the WHO and Suster and Moran (S&M) histological classifications and to the Masaoka–Koga and tumor, node and metastases (TNM) staging systems. The correlation of CT features with histology and stage and the prognostic role of histopathological and radiological features were assessed. Results: Five-year overall (OS) and disease-free survival (DFS) were 90.3% and 81.1%, respectively. A significant correlation of DFS with the Masaoka–Koga (p = 0.001) and TNM staging systems (p = 0.002) and with the S&M (p = 0.02) and WHO histological classifications (p = 0.04) was observed. CT scan features correlated with tumor stage, histology and prognosis. Moderately differentiated tumors (WHO B3) had a significantly higher incidence of irregular shape and contours (p = 0.002 and p = 0.001, respectively) and pericardial contact (p = 0.036). A larger tumor volume (p = 0.03) and a greater length of pleural contact (p = 0.04) adversely influenced DFS. The presence of pleural (p < 0.001) or lung invasion (p = 0.02) and of pleural effusion (p = 0.004) was associated with a significantly worse OS. Conclusions: Pre-operative CT scan parameters correlate with stage and histology, and have a prognostic role in surgically treated thymomas.

scholarly journals Efficacy and Benefit of Postoperative Chemotherapy in Micropapillray or Solid Predominant Pattern in Stage IB Lung Adenocarcinoma: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 8 ◽  
Author(s):  
Congcong Xu ◽  
Kanghao Zhu ◽  
Dong Chen ◽  
Yuhang Ruan ◽  
Zixian Jin ◽  
...  
Keyword(s):  
Overall Survival ◽  
Confidence Interval ◽  
Lung Adenocarcinoma ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
Hazard Ratio ◽  
Postoperative Chemotherapy ◽  
Free Survival ◽  
Stage Ib ◽  
Disease Free

Background: The benefit of postoperative chemotherapy remains controversial for patients with either a micropapillary or solid pattern in stage IB non-small cell lung cancer. This study is designed to explore the significance of postoperative chemotherapy in patients with either a micropapillary or solid pattern in stage IB lung adenocarcinoma.Method: To conduct the meta-analysis, PubMed, Cochrane Library, Embase and Medline were used to collect literature on long-term follow-up studies published before March, 2021, involving postoperative chemotherapy for patients with both a micropapillary or solid pattern in stage IB lung adenocarcinoma as compared to non-postoperative chemotherapy. Survival data was extracted from the literature, including the overall survival and disease-free survival. Based on overall survival and disease-free survival, hazard ratios and their 95% of confidence intervals were applied to assess the prognostic effect of postoperative chemotherapy. Review Manager software was used to merge the effect size for the meta-analysis.Result: In total, 6 papers with 956 patients were included. In terms of the prognosis of patients suffering from lung cancer when receiving postoperative chemotherapy, this study comprehensively reviews and evaluates the available evidence of micropapillary or solid patterns. After excluding the heterogeneity between the studies, we found that the pooled results from 6 studies report that postoperative chemotherapy was associated with a better overall survival rate when compared with non-postoperative chemotherapy (hazard ratio = 0.58, 95% confidence interval, 0.44–0.77; P = 0.0002). Postoperative chemotherapy also significantly improved the disease-free survival in patients with either a micropapillary or a solid pattern in stage IB lung adenocarcinoma (postoperative chemotherapy vs. non-postoperative chemotherapy, hazard ratio = 0.51, 95% confidence interval, 0.40–0.64; P &lt; 0.001). However, a subgroup analysis showed that compared with non-postoperative chemotherapy, tumor size was unrelated to the prognosis of patients in stage IB undergoing postoperative chemotherapy (hazard ratio = 0.98, 95% confidence interval, 0.94–1.02; P = 0.27).Conclusion: Postoperative chemotherapy results in a better long-term survival rate for patients with either a solid or a micropapillary pattern in stage IB lung adenocarcinoma. Multi-center, prospective, clinical trials are needed to validate our findings.

Prognostic Role of C-Reactive Protein in Breast Cancer: A Systematic Review and Meta-Analysis

2011 ◽  
Vol 26 (4) ◽  
pp. 209-215 ◽  
Author(s):  
Yijie Han ◽  
Feng Mao ◽  
Ying Wu ◽  
Xiaonan Fu ◽  
Wei Zhang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
C Reactive Protein ◽  
Cancer Specific Survival ◽  
Free Survival ◽  
Reactive Protein ◽  
Hazard Ratios ◽  
Disease Free

Background Recent studies have shown that C-reactive protein (CRP) may be associated with breast cancer. The purpose of this study is to summarize the predictive role of CRP for survival in breast cancer as shown in all available studies worldwide. Methods Related studies were identified and evaluated for quality through multiple search strategies. Data were collected from studies comparing overall, cancer-specific, and disease-free survival (OS, CSS, and DFS) in patients with elevated CRP levels and those having lower levels. Studies were pooled, and combined hazard ratios (HRs) of CRP for survival were calculated. Results A total of 10 studies (n=4,502) were included for this meta-analysis (9 for OS, 3 for CSS, and 3 for DFS). For overall and disease-free survival, the pooled HRs of CRP were significant at 1.62 (95% confidence interval [95% CI], 1.20-2.18) and 1.81 (95% CI, 1.44-2.26), respectively. For cancer-specific survival, the pooled HR in higher CRP expression in breast cancer was 2.08 (95% CI, 1.48-2.94), which could strongly predict poorer survival in breast cancer. Conclusions CRP has a critical prognostic value in patients with breast cancer as an inflammation biomarker.

scholarly journals Metastatic Lymph Node Ratio (mLNR) is a Useful Parameter in the Prognosis of Colorectal Cancer; A Meta-Analysis for the Prognostic Role of mLNR

Medicina ◽  
2019 ◽  
Vol 55 (10) ◽  
pp. 673 ◽  
Author(s):  
Pyo ◽  
Kim ◽  
Lee ◽  
Baek ◽  
Kang
Keyword(s):  
Lymph Node Ratio ◽  
Metastatic Lymph Node ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
Tumor Stage ◽  
Tumor Location ◽  
Free Survival ◽  
Node Ratio ◽  
Disease Free

Background and objectives: The presenting study aimed to elucidate the prognostic role of the metastatic lymph node ratio (mLNR) in patients with colorectal cancer (CRC), using a meta-analysis. Materials and Methods: Using data from 90,274 patients from 14 eligible studies, we performed a meta-analysis for the correlation between mLNR and survival rate. Besides, subgroup analyses were performed, based on tumor stage, tumor location, and mLNR. Results: A high mLNR showed significant correlation with worse overall survival and disease-free survival rates in CRC patients (hazard ratio (HR), 1.617, 95% confidence interval (CI) 1.393–1.877, and HR 2.345, 95% CI 1.879–2.926, respectively). In patients with stage III, who had regional LN metastasis, the HRs were 1.730 (95% CI 1.266–2.362) and 2.451 (95% CI 1.719–3.494) for overall and disease-free survival, respectively. According to tumor location, rectal cancer showed a worse survival rate when compared to colon cancer. In the analysis for overall survival, when mLNR was 0.2, HR was the highest across the different subgroups (HR 5.040, 95% CI 1.780–14.270). However, in the analysis for disease-free survival, the subgroup with an mLNR < 0.2 had a higher HR than the other subgroups (HR 2.878, 95% CI 1.401–5.912). Conclusions: The mLNR may be a useful prognostic factor for patients with CRC, regardless of the tumor stage or tumor location. Further studies are necessary for the detailed criteria of mLNR before its application in daily practice.

scholarly journals Meta-analysis of the prognostic significance of FOXC2 in various tumors

2019 ◽  
Vol 48 (3) ◽  
pp. 030006051989164
Author(s):  
Bixia Xu ◽  
Yun Tian ◽  
Lin Liu
Keyword(s):  
Cancer Patients ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Disease Free Survival ◽  
Final Analysis ◽  
Hazard Ratio ◽  
Cancer Specific Survival ◽  
Free Survival ◽  
Forkhead Box

Objective Many studies have focused on correlations between forkhead box protein C2 (FOXC2) and various tumors but discrepant results have been reported. Thus, we conducted this meta-analysis to assess the prognostic role of FOXC2 in tumors. Methods Four electronic databases (PubMed, Embase, Web of Science, and SinoMed) were screened through September 2019. Results The final analysis included 15 reports and 2115 patients; results suggested that cancer patients with FOXC2 had worse overall survival (hazard ratio 2.14, 95% confidence interval (CI) 1.74–2.64), cancer-specific survival (hazard ratio 2.65, 95% CI 1.44–4.89), and disease-free survival (hazard ratio 1.93, 95% CI 1.49–2.50) than patients lacking FOXC2. Conclusions The presence of FOXC2 was associated with poor survival in cancer patients. FOXC2 could be a promising prognostic marker in the future.

Sign in / Sign up

Export Citation Format

Share Document